SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series January recently filed with US Patent Office 01/10

20100022761 - Photocleavable linker methods and compositions: Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100022762 - Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate synthases: Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology with known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II... Agent: Howrey LLP

20100022763 - Sirna targeting kinase insert domain receptor (kdr): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20100022764 - Method and apparatus for producing cellulose acylate film, and cellulose acylate film: According to the present invention, the adaptability to producing the cellulose acylate film and the surface properties of the cellulose acylate film produced by means of the melt film-forming method can be remarkably improved. Accordingly, there is also improved the surface properties of a stretched cellulose acylate film produced by... Agent: Sughrue Mion, PLLC

20100022765 - Methods for extracting and purifying sucralose intermediate: The present invention provides a method for purifying sucralose-6-ester for use in making sucralose, wherein the method eliminates the need of an esterification process. In particular, ethyl acetate and ether are used to extract and purify sucralose-6-ester from a sucralose production intermediate composition comprising sucralose-6-ester.... Agent: Perkins Coie LLP

20100016565 - Identification and characterization of an anthocyanin mutant (ant1) in tomato: Flavonoids are obtained from plants that overexpress an ANT1 gene compared to wild-type plants. The plant may be a transgenic plant that contains a transformation vector that causes the overexpression of ANT1. Alternatively, the plant can be selectively bred to have an allele of or mutation in an endogenous ANT1... Agent: Klarquist Sparkman, LLP

20100016568 - Cellomics system: In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction... Agent: Antonelli, Terry, Stout & Kraus, LLP

20100016569 - Cellomics system: In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction... Agent: Antonelli, Terry, Stout & Kraus, LLP

20100016566 - Method of synthesizing cdna and method of synthesizing rna chains, and nucleotide-immobilized carrier: A method of synthesizing a cDNA chain using an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a group derived from a phosphoric ester composing the hydrophilic portion of phospholipid, and a second unit having a group derived from carboxylic acid having an... Agent: Smith, Gambrell & Russell

20100016567 - Process for producing di(pyrimidine nucleoside 5'-)polyphosphate: m

20100016570 - Modified family 6 glycosidases with altered substrate specificity: A modified Family 6 glycosidase enzyme comprising amino acid substitutions at one or more positions selected from the group 182, 367, 399, 400 and 427 is provided (the position determined form alignment of a parental Family 6 glycosidase with SEQ ID NO: 1). Genetic constructs and genetically modified microbes comprising... Agent: Fitzpatrick Cella Harper & Scinto

20100016571 - Peptide having ability to activate cancer-related gene: To provide a cancer diagnostic reagent for determining malignancy of a cancer patient or a cancer cell and a tendency of canceration of a healthy subject, the reagent including a peptide having an ability to activate a cancer-related gene and extracted from cell membrane surfaces of human squamous-cell carcinoma cells... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100016572 - Antigenic polypeptide se36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen: The present invention provides a polyeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum, at the erythrocyte stage, a process for purifing said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100016573 - Sirna targeting cyclin-dependent kinase inhibitor 1b (p27, kip1) (cdkn1b): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20100016574 - 2'-hydroxyl group-modified ribonucleoside derivatives: (wherein R1 represents a hydrogen atom or the like, R2 represents a hydrogen atom or the like, R3 represents a methyl group or the like, and B represents a nucleic acid base residue optionally having a protecting group or a modifying group). An RNA containing this ribonucleoside derivative shows excellent... Agent: Birch Stewart Kolasch & Birch

20100016575 - Bacterial cellulose-containing formulations lacking a carboxymethyl cellulose component: A method for the production of a bacterial cellulose-containing formulation that lacks a carboxymethyl cellulose component. The method includes providing a bacterial cellulose product, mixing the bacterial cellulose product with a polymeric thickener and/or a precipitation agent, lysing the bacterial cells from the bacterial cellulose product or the mixture of... Agent: Sutherland Asbill & Brennan LLP

20100016576 - Method for the extraction of starch from corn: A method of extracting starch from corn. The method comprises steeping ground corn in a mixture of ammonium hydroxide and water, for a period of between 45 minutes and 20 hours wherein the mixture has a pH level between about 11.3 and 11.4. This method provides the advantage of extracting... Agent: Zarley Law Firm P.L.C

20100016577 - Method for production of limulus-positive glycolipid, the limulus-positive glycolipid, and composition containing the limulus-positive glycolipid: It has been found that a limulus-positive glycolipid is present in xanthan gum derived from Xanthomonas, which has been commercially available and eaten for many years, and this was purified, and it has been found that this limulus-positive glycolipid has an immunopotentiation effect. A method for safely and inexpensively producing... Agent: Edwards Angell Palmer & Dodge LLP

20100010205 - Naphthalene 2-carboxylate derivative useful for synthesizing gemcitabine and a method for preparing the same: Disclosed herein are novel naphthalene-2-carboxylate derivatives of Formula (I), which are useful for the synthesis of gemcitabine, as well as a preparation method. The novel derivatives have naphthalene-2-carboxlate as the hydroxy protecting group of 2-deoxy-2,2-difluoro-pentofuranose-1-ulose. (I) wherein R1 and R2 are each independently hydrogen, methyl, chloro, fluoro, bromo, iodo, methoxy,... Agent: Lucas & Mercanti, LLP

20100010207 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100010206 - Sirna targeting hypoxia-inducible factor 1: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.... Agent: Kalow & Springut LLP

20100010209 - Method and apparatus for combinatorial chemistry: A method and apparatus are provided for performing light-directed reactions in spatially addressable channels within a plurality of channels. One aspect of the invention employs photoactivatable reagents in solutions disposed into spatially addressable flow streams to control the parallel synthesis of molecules immobilized within the channels. The reagents may be... Agent: Luedeka, Neely & Graham, P.C.

20100010208 - Purification of a triple helix formation with an immobilized oligonucleotide: Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100010210 - Vaccine: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100010211 - Vaccine: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100004432 - Aptamer against midkine and use thereof: An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100004433 - Novel collagen-like protein clac, precursor thereof and genes encoding the same: A novel human collagen-like protein CLAC occurring in brain amyloid and its precursor CLAC-P; genes encoding the same; cDNA of mouse CLAC-P and its deduced amino acid sequence; antibodies specific to these proteins; and methods of diagnosing treating and preventing Alzheimer's disease by using the same.... Agent: Studebaker & Brackett PC

20100004434 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100004435 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100004436 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100004437 - Chemical transformation of lignocellulosic biomass into fuels and chemicals: A method for converting a carbohydrate to a furan in a polar aprotic solvent in the presence of a chloride, bromide, or iodide salt or a mixture thereof and optionally in the presence of an acid catalyst, a metal halide catalyst and/or an ionic liquid (up to 40 wt %).... Agent: Greenlee Winner And Sullivan P C